Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Memantine].

J L Molinuevo1

  • 1Unidad de Memoria-Alzheimer Servicio de Neurología-ICMSN Hospital Clinic i Universitari, Barcelona, Spain. jlmoli@clinic.ub.es

Neurologia (Barcelona, Spain)
|May 28, 2003
PubMed
Summary
This summary is machine-generated.

Memantine, an N-methyl-D-aspartate (NMDA) receptor antagonist, offers neuroprotection and symptomatic relief for advanced Alzheimer's disease (AD). This review explores its mechanisms and benefits in dementia treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparative Analysis of Different Definitions of Amyloid-β Positivity to Detect Early Downstream Pathophysiological Alterations in Preclinical Alzheimer.

The journal of prevention of Alzheimer's disease·2020
Same author

The European Prevention of Alzheimer's Dementia (EPAD) Longitudinal Cohort Study: Baseline Data Release V500.0.

The journal of prevention of Alzheimer's disease·2020
Same author

Anti-Tau Trials for Alzheimer's Disease: A Report from the EU/US/CTAD Task Force.

The journal of prevention of Alzheimer's disease·2019
Same author

Registries and Cohorts to Accelerate Early Phase Alzheimer's Trials. A Report from the E.U./U.S. Clinical Trials in Alzheimer's Disease Task Force.

The journal of prevention of Alzheimer's disease·2017
Same author

Cerebrospinal fluid-induced retardation of amyloid β aggregation correlates with Alzheimer's disease and the APOE ε4 allele.

Brain research·2016
Same author

Clinical and biomarker profiling of prodromal Alzheimer's disease in workpackage 5 of the Innovative Medicines Initiative PharmaCog project: a 'European ADNI study'.

Journal of internal medicine·2016
Same journal

[Amyotrophic neuralgia secondary to Vaxzevria (AstraZeneca) COVID-19 vaccine].

Neurologia (Barcelona, Spain)·2024
Same journal

[SARS-CoV-2 infection: Possible underdiagnosis of cerebral venous sinus thrombosis].

Neurologia (Barcelona, Spain)·2024
Same journal

[Bell's palsy following COVID-19 vaccination: A case report].

Neurologia (Barcelona, Spain)·2024
Same journal

[Parsonage-Turner syndrome post-infection by SARS-CoV-2: A case report].

Neurologia (Barcelona, Spain)·2024
Same journal

[Acute transverse myelitis following SARS-CoV-2 infection].

Neurologia (Barcelona, Spain)·2024
Same journal

[Neurological complications in critical patients with COVID-19].

Neurologia (Barcelona, Spain)·2024
See all related articles

Area of Science:

  • Neuroscience
  • Pharmacology

Context:

  • Alzheimer's disease (AD) is a prevalent form of dementia with limited neuroprotective treatments.
  • Current AD therapies primarily offer symptomatic benefits without addressing underlying neurodegeneration.

Purpose:

  • To review the neuroprotective and symptomatic therapeutic potential of memantine, an N-methyl-D-aspartate (NMDA) receptor antagonist.
  • To explore the mechanisms of glutamatergic neurodegeneration and glutamate's role in cognition.

Summary:

  • Memantine, an NMDA receptor antagonist, is approved for advanced AD, demonstrating neuroprotective effects in preclinical studies.
  • Its mechanism of action supports its use as both a symptomatic treatment for AD and vascular dementia and a neuroprotective agent.
  • The review covers glutamate's role in neurodegeneration and cognitive function.

Related Experiment Videos

Impact:

  • Highlights memantine's dual role in managing Alzheimer's disease symptoms and potentially slowing neurodegeneration.
  • Provides insights into glutamatergic pathways relevant to neurodegenerative diseases.
  • Informs therapeutic strategies for dementia by reviewing memantine's efficacy and mechanisms.